|
US4487603A
(en)
|
1982-11-26 |
1984-12-11 |
Cordis Corporation |
Implantable microinfusion pump system
|
|
US4501729A
(en)
|
1982-12-13 |
1985-02-26 |
Research Corporation |
Aerosolized amiloride treatment of retained pulmonary secretions
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US4486194A
(en)
|
1983-06-08 |
1984-12-04 |
James Ferrara |
Therapeutic device for administering medicaments through the skin
|
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
|
US4959217A
(en)
|
1986-05-22 |
1990-09-25 |
Syntex (U.S.A.) Inc. |
Delayed/sustained release of macromolecules
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
US4925678A
(en)
|
1987-04-01 |
1990-05-15 |
Ranney David F |
Endothelial envelopment drug carriers
|
|
US5080646A
(en)
|
1988-10-03 |
1992-01-14 |
Alza Corporation |
Membrane for electrotransport transdermal drug delivery
|
|
US5091513A
(en)
|
1987-05-21 |
1992-02-25 |
Creative Biomolecules, Inc. |
Biosynthetic antibody binding sites
|
|
JP3012244B2
(ja)
|
1987-09-21 |
2000-02-21 |
ジェン―プローブ インコーポレイテッド |
ヌクレオチドプローブ用非ヌクレオチド連結試薬
|
|
US5096815A
(en)
|
1989-01-06 |
1992-03-17 |
Protein Engineering Corporation |
Generation and selection of novel dna-binding proteins and polypeptides
|
|
US5167616A
(en)
|
1989-12-14 |
1992-12-01 |
Alza Corporation |
Iontophoretic delivery method
|
|
US6153737A
(en)
|
1990-01-11 |
2000-11-28 |
Isis Pharmaceuticals, Inc. |
Derivatized oligonucleotides having improved uptake and other properties
|
|
US5214136A
(en)
|
1990-02-20 |
1993-05-25 |
Gilead Sciences, Inc. |
Anthraquinone-derivatives oligonucleotides
|
|
US5138045A
(en)
|
1990-07-27 |
1992-08-11 |
Isis Pharmaceuticals |
Polyamine conjugated oligonucleotides
|
|
US5378825A
(en)
|
1990-07-27 |
1995-01-03 |
Isis Pharmaceuticals, Inc. |
Backbone modified oligonucleotide analogs
|
|
US6335434B1
(en)
|
1998-06-16 |
2002-01-01 |
Isis Pharmaceuticals, Inc., |
Nucleosidic and non-nucleosidic folate conjugates
|
|
US5225182A
(en)
|
1991-10-31 |
1993-07-06 |
Sharma Yash P |
Vectored drug delivery system using a cephaloplastin linking agent and a methed of using the system
|
|
JP3131222B2
(ja)
|
1991-12-24 |
2001-01-31 |
アイシス・ファーマシューティカルス・インコーポレーテッド |
ギャップを有する２′修飾オリゴヌクレオチド
|
|
EP0642589A4
(en)
|
1992-05-11 |
1997-05-21 |
Ribozyme Pharm Inc |
METHOD AND REAGENT TO INHIBIT VIRAL REPLICATION.
|
|
US6582728B1
(en)
|
1992-07-08 |
2003-06-24 |
Inhale Therapeutic Systems, Inc. |
Spray drying of macromolecules to produce inhaleable dry powders
|
|
EP0786522A2
(en)
|
1992-07-17 |
1997-07-30 |
Ribozyme Pharmaceuticals, Inc. |
Enzymatic RNA molecules for treatment of stenotic conditions
|
|
US6235886B1
(en)
|
1993-09-03 |
2001-05-22 |
Isis Pharmaceuticals, Inc. |
Methods of synthesis and use
|
|
ATE227342T1
(de)
|
1993-09-02 |
2002-11-15 |
Ribozyme Pharm Inc |
Enzymatische nukleiksaüre die nicht-nukleotide enthaltet
|
|
ATE247128T1
(de)
|
1993-09-03 |
2003-08-15 |
Isis Pharmaceuticals Inc |
Aminoderivatisierte nukleoside und oligonukleoside
|
|
US5624803A
(en)
|
1993-10-14 |
1997-04-29 |
The Regents Of The University Of California |
In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom
|
|
ATE174600T1
(de)
|
1993-10-27 |
1999-01-15 |
Ribozyme Pharm Inc |
2'-amido-und 2'-peptido-modifizierte oligonukleotide
|
|
US6051256A
(en)
|
1994-03-07 |
2000-04-18 |
Inhale Therapeutic Systems |
Dispersible macromolecule compositions and methods for their preparation and use
|
|
US6447796B1
(en)
|
1994-05-16 |
2002-09-10 |
The United States Of America As Represented By The Secretary Of The Army |
Sustained release hydrophobic bioactive PLGA microspheres
|
|
CA2207593A1
(en)
|
1994-12-13 |
1996-06-20 |
John Gustofson |
Method and reagent for treatment of arthritic conditions, induction of graft tolerance and reversal of immune responses
|
|
US5898031A
(en)
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
|
JP3756313B2
(ja)
|
1997-03-07 |
2006-03-15 |
武 今西 |
新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
|
|
US6251666B1
(en)
|
1997-03-31 |
2001-06-26 |
Ribozyme Pharmaceuticals, Inc. |
Nucleic acid catalysts comprising L-nucleotide analogs
|
|
US6235310B1
(en)
|
1997-04-04 |
2001-05-22 |
Valentis, Inc. |
Methods of delivery using cationic lipids and helper lipids
|
|
US6395713B1
(en)
|
1997-07-23 |
2002-05-28 |
Ribozyme Pharmaceuticals, Inc. |
Compositions for the delivery of negatively charged molecules
|
|
AR013269A1
(es)
|
1997-08-04 |
2000-12-13 |
Scras |
Producto que contiene por lo menos un rna de doble filamento combinado con por lo menos un agente anti-viral, para la utilizacion terapeutica en eltratamiento de una enfermedad viral, en especial de la hepatitis viral
|
|
JP4236812B2
(ja)
|
1997-09-12 |
2009-03-11 |
エクシコン エ／エス |
オリゴヌクレオチド類似体
|
|
US6565885B1
(en)
|
1997-09-29 |
2003-05-20 |
Inhale Therapeutic Systems, Inc. |
Methods of spray drying pharmaceutical compositions
|
|
CA2315256A1
(en)
|
1997-12-16 |
1999-06-24 |
Valentis, Inc. |
Needle-free injection of formulated nucleic acid molecules
|
|
US6506559B1
(en)
|
1997-12-23 |
2003-01-14 |
Carnegie Institute Of Washington |
Genetic inhibition by double-stranded RNA
|
|
DE69941447D1
(de)
|
1998-01-05 |
2009-11-05 |
Univ Washington |
Erhöhter transport unter benutzung membranzerstörender stoffe
|
|
AR020078A1
(es)
|
1998-05-26 |
2002-04-10 |
Syngenta Participations Ag |
Metodo para alterar la expresion de un gen objetivo en una celula de planta
|
|
GB9827152D0
(en)
|
1998-07-03 |
1999-02-03 |
Devgen Nv |
Characterisation of gene function using double stranded rna inhibition
|
|
AU747597B2
(en)
|
1998-07-20 |
2002-05-16 |
Inex Pharmaceuticals Corporation |
Liposomal encapsulated nucleic acid-complexes
|
|
CA2361201A1
(en)
|
1999-01-28 |
2000-08-03 |
Medical College Of Georgia Research Institute, Inc. |
Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
|
|
DE19956568A1
(de)
|
1999-01-30 |
2000-08-17 |
Roland Kreutzer |
Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
|
|
ES2234563T5
(es)
|
1999-02-12 |
2018-01-17 |
Daiichi Sankyo Company, Limited |
Nuevos análogos de nucleósidos y oligonucleótidos
|
|
DE60040274D1
(de)
|
1999-03-10 |
2008-10-30 |
Phogen Ltd |
Verabreichung von nukleinsäuren und proteinen an zellen
|
|
HK1047109A1
(zh)
|
1999-10-15 |
2003-02-07 |
University Of Massachusetts |
作为指定基因干预工具的rna干预轨迹基因
|
|
GB9927444D0
(en)
|
1999-11-19 |
2000-01-19 |
Cancer Res Campaign Tech |
Inhibiting gene expression
|
|
ES2336887T5
(es)
|
2000-03-30 |
2019-03-06 |
Whitehead Inst Biomedical Res |
Mediadores de interferencia por ARN específicos de secuencias de ARN
|
|
US20040038241A1
(en)
|
2000-07-26 |
2004-02-26 |
Martin Glennsbjerg |
Spatially resolved enzyme-linked assay
|
|
US20020130430A1
(en)
|
2000-12-29 |
2002-09-19 |
Castor Trevor Percival |
Methods for making polymer microspheres/nanospheres and encapsulating therapeutic proteins and other products
|
|
WO2002087541A1
(en)
|
2001-04-30 |
2002-11-07 |
Protiva Biotherapeutics Inc. |
Lipid-based formulations for gene transfer
|
|
US6586524B2
(en)
|
2001-07-19 |
2003-07-01 |
Expression Genetics, Inc. |
Cellular targeting poly(ethylene glycol)-grafted polymeric gene carrier
|
|
US20040063654A1
(en)
|
2001-11-02 |
2004-04-01 |
Davis Mark E. |
Methods and compositions for therapeutic use of RNA interference
|
|
AUPR894201A0
(en)
|
2001-11-19 |
2001-12-13 |
Women's And Children's Hospital |
Respiratory delivery for gene therapy and lentiviral delivery particle
|
|
US7060498B1
(en)
|
2001-11-28 |
2006-06-13 |
Genta Salus Llc |
Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers
|
|
US7141540B2
(en)
|
2001-11-30 |
2006-11-28 |
Genta Salus Llc |
Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof
|
|
DE60310944T3
(de)
|
2002-08-05 |
2017-08-03 |
Silence Therapeutics Gmbh |
Weitere neue formen von interferierende rns moleküle
|
|
AU2003261449A1
(en)
|
2002-08-07 |
2004-02-25 |
|
Compositions for rna interference and methods of use thereof
|
|
ATE443765T1
(de)
|
2003-03-21 |
2009-10-15 |
Santaris Pharma As |
Analoga kurzer interferierender rna (sirna)
|
|
US20050136437A1
(en)
|
2003-08-25 |
2005-06-23 |
Nastech Pharmaceutical Company Inc. |
Nanoparticles for delivery of nucleic acids and stable double-stranded RNA
|
|
US20060058255A1
(en)
*
|
2004-03-01 |
2006-03-16 |
Jianzhu Chen |
RNAi-based therapeutics for allergic rhinitis and asthma
|
|
US20070265220A1
(en)
|
2004-03-15 |
2007-11-15 |
City Of Hope |
Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
|
|
CA2559955C
(en)
|
2004-03-15 |
2016-02-16 |
City Of Hope |
Methods and compositions for the specific inhibition of gene expression by double-stranded rna
|
|
US7081836B2
(en)
|
2004-07-09 |
2006-07-25 |
The Johns Hopkins University |
Method and apparatus for covertly detecting and reporting a distress condition in a vehicle control cabin
|
|
US7358223B2
(en)
|
2004-10-04 |
2008-04-15 |
Nitto Denko Corporation |
Biodegradable cationic polymers
|
|
WO2006047842A2
(en)
|
2004-11-08 |
2006-05-11 |
K.U. Leuven Research And Development |
Modified nucleosides for rna interference
|
|
HUE056941T2
(hu)
|
2004-12-22 |
2022-04-28 |
Nitto Denko Corp |
Gyógyszerhordozó és gyógyszerhordozó kit fibrózis gátlására
|
|
WO2007041218A2
(en)
*
|
2005-09-30 |
2007-04-12 |
Oklahoma Medical Research Foundation |
Regulation of tool-like receptors on stem cells
|
|
EP1989307B1
(en)
|
2006-02-08 |
2012-08-08 |
Quark Pharmaceuticals, Inc. |
NOVEL TANDEM siRNAS
|
|
EP1881080A1
(en)
*
|
2006-07-18 |
2008-01-23 |
Institut Gustave Roussy |
Toll like receptor 4 dysfunction and the biological applications thereof
|
|
JP2010507387A
(ja)
*
|
2006-10-25 |
2010-03-11 |
クアーク・ファーマスーティカルス、インコーポレイテッド |
新規のｓｉＲＮＡおよびその使用方法
|
|
JP2010527914A
(ja)
|
2007-04-26 |
2010-08-19 |
クォーク ファーマシューティカルズ インコーポレーティッド |
呼吸器系への抑制性核酸分子の治療的送達
|
|
WO2008154008A1
(en)
*
|
2007-06-11 |
2008-12-18 |
The Scripps Research Institute |
Methods and compositions for inhibiting toll-like receptor mediated immune responses
|
|
WO2009015107A1
(en)
*
|
2007-07-20 |
2009-01-29 |
Yeda Research And Development Co. Ltd. |
Modulation of toll-like receptors for controlling neurogenesis
|
|
EP2170366B1
(en)
|
2007-08-03 |
2013-11-06 |
Opsona Therapeutics Limited |
Use of tlr-2 antagonists for treatment of reperfusion injury and tissue damage
|
|
KR20110081336A
(ko)
|
2008-11-04 |
2011-07-13 |
이데라 파마슈티칼즈, 인코포레이티드 |
안티센스 올리고누클레오티드에 의한 ｔｏｌｌ―유사 수용체 2 발현의 조절
|
|
US20100111936A1
(en)
|
2008-11-04 |
2010-05-06 |
Idera Pharmaceuticals, Inc. |
Modulation of Toll-Like Receptor 4 Expression by Antisense Oligonucleotides
|
|
AU2010233151A1
(en)
*
|
2009-04-09 |
2011-11-17 |
The University Of North Carolina At Chapel Hill |
Methods of treating edema related to ischemia-reperfusion
|
|
GB0908425D0
(en)
|
2009-05-15 |
2009-06-24 |
Medical Res Council |
Medical use
|
|
AU2010324658A1
(en)
|
2009-11-26 |
2012-05-03 |
Quark Pharmaceuticals, Inc. |
siRNA compounds comprising terminal substitutions
|
|
EP2681314B1
(en)
|
2011-03-03 |
2017-11-01 |
Quark Pharmaceuticals, Inc. |
Compositions and methods for treating lung disease and injury
|
|
CA2828544A1
(en)
|
2011-03-03 |
2012-09-07 |
Quark Pharmaceuticals, Inc. |
Oligonucleotide modulators of the toll-like receptor pathway
|